• 목록
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional treatment and medications do not work for many patients suffering from depression. The individual approach to treatment could be the solution.

Cue is a digital intervention platform that converts passively collected sensor data from smartphones into customized micro-interventions to improve mental health. We analysed the best-fit personalized ML models for each subject using Shapley values to discover their feature predictors and reveal distinct characteristics that can be used to predict changes in mood with time.

Predictors of Mood

Depression is among the most prevalent causes of mental illness.1 Yet, only half of people suffering from the condition receive treatment1. To improve outcomes, healthcare professionals must be able identify and treat patients who are the most likely to respond to specific treatments.

Personalized depression during pregnancy treatment treatment is one way to do this. Researchers at the University of Illinois Chicago are developing new methods for predicting which patients will gain the most from certain treatments. They make use of mobile phone sensors, a voice assistant with artificial intelligence as well as other digital tools. Two grants totaling more than $10 million will be used to identify biological and behavior predictors of response.

The majority of research to so far has focused on clinical and sociodemographic characteristics. These include demographic variables such as age, sex and education, clinical characteristics such as symptoms severity and comorbidities and biological indicators such as neuroimaging and genetic variation.

While many of these aspects can be predicted from information available in medical records, only a few studies have utilized longitudinal data to determine the factors that influence mood in people. They have not taken into account the fact that moods vary significantly between individuals. Therefore, it is essential to develop methods that allow for the determination of different mood predictors for each person and treatment effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team will then create algorithms to identify patterns of behaviour and emotions that are unique to each individual.

The team also devised an algorithm for machine learning to identify dynamic predictors of each person's depression mood. The algorithm combines these personal differences into a unique "digital phenotype" for each participant.

The digital phenotype was associated with CAT DI scores, a psychometrically validated symptom severity scale. However the correlation was not strong (Pearson's r = 0.08, BH-adjusted P-value of 3.55 1003) and varied widely among individuals.

Predictors of symptoms

depression in elderly treatment is one of the most prevalent causes of disability1 yet it is often untreated and not diagnosed. Depressive disorders are often not treated due to the stigma attached to them and the lack of effective interventions.

To aid in the development of a personalized treatment plan, identifying predictors of symptoms is important. However, the methods used to predict symptoms rely on clinical interview, which is unreliable and only detects a small number of symptoms related to depression.2

Machine learning can enhance the accuracy of diagnosis and treatment for depression by combining continuous, digital behavioral phenotypes collected from smartphone sensors with a valid mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). Digital phenotypes can provide continuous, high-resolution measurements as well as capture a wide variety of distinctive behaviors and activity patterns that are difficult to document with interviews.

The study enrolled University of California Los Angeles (UCLA) students experiencing mild to severe depressive symptoms participating in the Screening and Treatment for Anxiety and Depression (STAND) program29, which was developed under the UCLA Depression Grand Challenge. Participants were referred to online assistance or in-person clinics according to the severity of their depression. Those with a CAT-DI score of 35 or 65 were assigned online support with the help of a peer coach. those who scored 75 patients were referred to in-person psychotherapy.

At the beginning of the interview, participants were asked a series of questions about their personal characteristics and psychosocial traits. The questions covered age, sex, and education as well as marital status, financial status and whether they were divorced or not, the frequency of suicidal thoughts, intentions or attempts, as well as how often they drank. Participants also rated their degree of depression symptom severity on a 0-100 scale using the CAT-DI. CAT-DI assessments were conducted every other week for participants that received online support, and once a week for those receiving in-person support.

Predictors of Treatment Reaction

Research is focusing on personalization of Extreme depression Treatment treatment. Many studies are focused on finding predictors, which can aid clinicians in identifying the most effective medications to treat each patient. Pharmacogenetics, for instance, uncovers genetic variations that affect the way that our bodies process drugs. This lets doctors select the medication that will likely work best for every patient, minimizing time and effort spent on trials and errors, while avoid any negative side effects.

Another approach that is promising is to develop prediction models that combine the clinical data with neural imaging data. These models can be used to identify the most appropriate combination of variables that is predictors of a specific outcome, such as whether or not a particular medication is likely to improve symptoms and mood. These models can be used to predict the response of a patient to a treatment, allowing doctors to maximize the effectiveness.

A new generation employs machine learning techniques such as supervised and classification algorithms, regularized logistic regression and tree-based methods to integrate the effects from multiple variables to improve the accuracy of predictive. These models have been demonstrated to be useful in predicting treatment outcomes, such as response to antidepressants. These models are getting more popular in psychiatry and it is likely that they will become the standard for the future of clinical practice.

In addition to prediction models based on ML The study of the mechanisms behind depression continues. Recent findings suggest that depression is connected to the dysfunctions of specific neural networks. This suggests that an individualized treatment for depression will be based upon targeted treatments for depression that restore normal function to these circuits.

One way to do this is by using internet-based programs that can provide a more individualized and personalized experience for patients. One study found that a program on the internet was more effective than standard care in alleviating symptoms and ensuring an improved quality of life ect for treatment resistant depression people with MDD. A controlled, randomized study of an individualized treatment for depression found that a significant percentage of patients saw improvement over time and fewer side consequences.

Predictors of side effects

A major issue in personalizing depression treatment is predicting the antidepressant medications that will have very little or no side effects. Many patients take a trial-and-error method, involving a variety of medications prescribed before finding one that is effective and tolerable. Pharmacogenetics is an exciting new avenue for a more efficient and specific approach to choosing antidepressant medications.

There are several predictors that can be used to determine the antidepressant that should be prescribed, such as gene variations, phenotypes of the patient such as gender or ethnicity, and comorbidities. To identify the most reliable and valid predictors for a particular treatment, random controlled trials with larger samples will be required. This is due to the fact that it can be more difficult to determine interactions or moderators in trials that only include a single episode per person rather than multiple episodes over a period of time.

Additionally, the prediction of a patient's reaction to a particular medication will also likely need to incorporate information regarding the symptom profile and comorbidities, and the patient's previous experience with tolerability and efficacy. Currently, only a few easily measurable sociodemographic variables as well as clinical variables appear to be reliably related to response to MDD. These include gender, age, race/ethnicity as well as BMI, SES and the presence of alexithymia.

Many issues remain to be resolved when it comes to the use of pharmacogenetics to treat depression. First, it is essential to have a clear understanding and definition of the genetic mechanisms that cause depression, as well as an accurate definition of an accurate indicator of the response to treatment. Ethics, such as privacy, and the responsible use of genetic information should also be considered. Pharmacogenetics can, in the long run help reduce stigma around mental health treatments and improve the quality of treatment. However, as with any approach to psychiatry careful consideration and implementation is required. At present, it's ideal to offer patients an array of prenatal depression treatment medications that work and encourage them to speak openly with their doctor.